Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Asthenia, Blood pressure measurement, COVID-19
Clinical narrative: may have been little weak for 7-10 days; felt a little run down; headache-pain behind eyes; Loss of taste after the 1st dose; Loss of smell; Diagnosed with COVID-19 after 1st dose; feel sick; runny nose; nasal congestion; diarrhea; cough; nausea; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Diagnosed with COVID-19 after 1st dose), MALAISE (feel sick), AGEUSIA (Loss of taste after the 1st dose), ANOSMIA (Loss of smell) and RHINORRHOEA (runny nose) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017821A and 009C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension since 1996, Diabetes since 2012, Obesity, Acid reflux (oesophageal) since 1996 and Gout since 1999. Concomitant products included METFORMIN from 2012 to an unknown date and PIOGLITAZONE HYDROCHLORIDE (ACTOS) for Diabetes, ALLOPURINOL for Gout, METOPROLOL from 1996 to an unknown date and LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) for Hypertension.   On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Mar-2021, the patient experienced MALAISE (feel sick). On 02-Apr-2021, the patient experienced COVID-19 (Diagnosed with COVID-19 after 1st dose). On 02-Apr-2021 at 6:00 AM, the patient experienced AGEUSIA (Loss of taste after the 1st dose), ANOSMIA (Loss of smell) and HEADACHE (headache-pain behind eyes). On 04-Apr-2021, the patient experienced FEELING ABNORMAL (felt a little run down). On 16-Apr-2021, the patient experienced ASTHENIA (may have been little weak for 7-10 days). On an unknown date, the patient experienced RHINORRHOEA (runny nose), NASAL CONGESTION (nasal congestion), DIARRHOEA (diarrhea), COUGH (cough), NAUSEA (nausea) and VOMITING (Vomiting). The patient was treated with GUAIFENESIN (ROBITUSSIN [GUAIFENESIN]) (oral) at an unspecified dose and frequency; CHLORPHENAMINE MALEATE, PARACETAMOL, PSEUDOEPHEDRINE HYDROCHLORIDE (TYLENOL COLD + FLU) (oral) at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 12-Apr-2021, AGEUSIA (Loss of taste after the 1st dose) and ANOSMIA (Loss of smell) had resolved. On 15-Apr-2021, HEADACHE (headache-pain behind eyes) had resolved. On 16-Apr-2021, FEELING ABNORMAL (felt a little run down) had resolved. At the time of the report, COVID-19 (Diagnosed with COVID-19 after 1st dose), MALAISE (feel sick) and ASTHENIA (may have been little weak for 7-10 days) outcome was unknown and RHINORRHEA (runny nose), NASAL CONGESTION (nasal congestion), DIARRHEA (diarrhea), COUGH (cough), NAUSEA (nausea) and VOMITING (Vomiting) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Apr-2021, Polymerase chain reaction positive: positive (Positive) positive. On an unknown date, Blood pressure measurement: <90/<60 mmHg (Low) low.         Most recent FOLLOW-UP information incorporated above includes: On 06-Aug-2021: Updated reporter details,patient demographics, past medical history, lab data, suspect product dose 1 route of administration,anatomical location,dose 2 details concomitant, treatment medications and events were added.